{"id":113995,"date":"2022-11-02T17:39:36","date_gmt":"2022-11-02T17:39:36","guid":{"rendered":"https:\/\/www.aquatb.com\/?p=113995"},"modified":"2023-04-17T15:07:24","modified_gmt":"2023-04-17T15:07:24","slug":"biotech-stocks-the-top-5-to-watch-as-shares-trend","status":"publish","type":"post","link":"https:\/\/www.aquatb.com\/?p=113995","title":{"rendered":"Biotech Stocks: The Top 5 To Watch As Shares Trend Down Investor&#8217;s Business Daily"},"content":{"rendered":"<div id=\"toc\" style=\"background: #f9f9f9;border: 1px solid #aaa;display: table;margin-bottom: 1em;padding: 1em;width: 350px;\">\n<p class=\"toctitle\" style=\"font-weight: 700;text-align: center;\">Contents:<\/p>\n<ul class=\"toc_list\">\n<li><a href=\"#toc-0\">What are biotech stocks?<\/a><\/li>\n<li><a href=\"#toc-1\">What Are Biotechnology Stocks?<\/a><\/li>\n<li><a href=\"#toc-2\">Best Biotech Stocks: Twist Bioscience (TWST)<\/a><\/li>\n<li><a href=\"#toc-3\">Top Stocks To Invest In<\/a><\/li>\n<\/ul>\n<\/div>\n<p><img decoding=\"async\" class='wp-post-image' style='display: block;margin-left:auto;margin-right:auto;' src=\"https:\/\/forex-world.net\/wp-content\/uploads\/2021\/03\/image-vXW7nFem9Nxuir6d.jpeg\" width=\"301px\" alt=\"fda\"\/><br \/>\n<img decoding=\"async\" class='wp-post-image' style='display: block;margin-left:auto;margin-right:auto;' src=\"https:\/\/forex-world.net\/wp-content\/uploads\/2021\/03\/image-M2Doh3i5WOxeQBV1.jpeg\" width=\"308px\" alt=\"quarter\"\/><\/p>\n<p>Biotechnology stocks are the  instruments that help fund biotech companies. Many biotech companies fly under the radar of consumers and retail investors. That\u2019s because once they develop new drug technology, they sell it to a pharmaceutical company that can mass produce the product. However, biotechnology does not only target viruses in its drug development efforts.<\/p>\n<p>During the go-go pandemic days of IPOs, SPACs, and generous venture funding rounds, biotechnology companies raised too much money before they were ready to justify it. The stocks of some of these companies traded as little as 200 times a day. Moderna\u2019s average daily trading volume, by contrast, is 5.6 million.<\/p>\n<h2 id=\"toc-0\">What are biotech stocks?<\/h2>\n<p>Included in this score is a Quality Grade of B, due to the company&#8217;s track record of successful drug development and patent protection for core products. The biotech firm\u2019s financial future is also promising, according to investors and analysts. MarketBeat gives CRISPR stock a \u201chold\u201d rating and Yahoo Finance cites a consensus \u201cbuy\u201d among 23 analysts. News &#038; World Report and Investor\u2019s Business Daily, have listed CRISPR as a top biotech pick.<\/p>\n<p><img decoding=\"async\" class='aligncenter' style='display: block;margin-left:auto;margin-right:auto;' src=\"https:\/\/forex-world.net\/wp-content\/uploads\/2021\/12\/forex_featured009.jpg\" width=\"307px\" alt=\"worth $\"\/><\/p>\n<p>The Boston-based company Atea Pharmaceuticals has had a rollercoaster ride in the last 12 months. In Achilles\u2019 third quarter report, the company lamented the translation of its books and records from British pounds sterling into U.S. dollars, as the pound is currently very low against the dollar. Those that invest in the companies responsible for tomorrow\u2019s breakthroughs will enjoy substantial profits. They have already arrived in Europe, and sales of Humira have dropped by 15 percent since their introduction.<\/p>\n<p>Sales of its biggest product, Primatene Mist, edged 4% higher to $22.3 million. Through a deal with Eisai , Catalyst now sells anti-seizure medicine Fycompa in the U.S. Catalyst also sells Firdapse, a treatment for Lambert-Eaton myasthenic syndrome, or LEMS.<\/p>\n<h2 id=\"toc-1\">What Are Biotechnology Stocks?<\/h2>\n<p>The Food and Drug Administration approved 378 new drugs between 2010 and 2019, a big chunk of which were cancer medicines. Biotechnology companies played a big role in developing many of these new treatments, and their successes could partly be seen in the stock market, where biotech stocks soared. Biogen also has a Quality Grade of B due to being one of the leading biotech stocks developing treatments for neurological diseases, even with its Aduhelm setback. It also has consistent royalty revenue for many of its franchises including MS drug Ocrevus, which saw a 29% increase in the last quarter. Plus, BIIB has a strong balance sheet with minimal debt and nearly $3 billion in cash. The performance of large-cap biotech stocks is strongly influenced by large-scale trends in the health care sector.<\/p>\n<p>Twist is one of the hundreds of companies, public and private, aiming to supply other drug companies with key research and production technology. As with companies that seek to create and sell drugs, there is enormous risk, but there are also huge markets on offer. An investor day over the summer showed promise with drugs for diabetes and kidney cancer.<\/p>\n<div style='border: grey dotted 1px;padding: 11px;'>\n<h3>These Up-and-Coming Stocks Are Screaming Buys Right Now &#8211; Nasdaq<\/h3>\n<p>These Up-and-Coming Stocks Are Screaming Buys Right Now.<\/p>\n<p>Posted: Thu, 13 Apr 2023 09:30:00 GMT [<a href='https:\/\/news.google.com\/rss\/articles\/CBMiV2h0dHBzOi8vd3d3Lm5hc2RhcS5jb20vYXJ0aWNsZXMvdGhlc2UtdXAtYW5kLWNvbWluZy1zdG9ja3MtYXJlLXNjcmVhbWluZy1idXlzLXJpZ2h0LW5vd9IBAA?oc=5' rel=\"nofollow\">source<\/a>]<\/p>\n<\/div>\n<p>\u201c<a href=\"https:\/\/forex-world.net\/blog\/best-biotech-stocks-to-buy-now-6-best-biotech\/\">Best biotech stocks to buy now<\/a> is a gene editing company focused on the development of CRISPR\/Cas9-based therapeutics. CRISPR\/Cas9 has created a new class of medicines, which are well suited for targeting rare diseases or other disorders that are caused by genetic mutations. The Morningstar US Biotechnology Index comprises stocks from companies involved in research, discovery, development, and the production of innovative drug and drug-related technologies. Genetic and mRNA technologies and vaccines are central to many of these biotech companies, which depend on innovation and the opportunity for growth. Regeneron Pharmaceuticals REGN, Vertex Pharmaceuticals VRTX, and Alnylam Pharmaceuticals ALNY are among the largest biotech companies in this index.<\/p>\n<h2 id=\"toc-2\">Best Biotech Stocks: Twist Bioscience (TWST)<\/h2>\n<p>Starting a gallery of the best biotech stocks with an exchange-traded fund can seem like a form of giving up. The company also plans to review the efficacy of a vaccine in a phase 1b\/2 clinical trial for the treatment of human papillomavirus-related cervical lesions. Pharvaris is developing oral drugs to treat and prevent the rare genetic condition hereditary angioedema . At present, the majority of treatments for HAE are injected, so oral medicines could allow a more comfortable alternative for patients.<\/p>\n<div style='border: black dotted 1px;padding: 14px;'>\n<h3>2 Top Biotech Stocks to Buy in April &#8211; The Motley Fool<\/h3>\n<p>2 Top Biotech Stocks to Buy in April.<\/p>\n<p>Posted: Tue, 04 Apr 2023 07:00:00 GMT [<a href='https:\/\/news.google.com\/rss\/articles\/CBMiT2h0dHBzOi8vd3d3LmZvb2wuY29tL2ludmVzdGluZy8yMDIzLzA0LzA0LzItdG9wLWJpb3RlY2gtc3RvY2tzLXRvLWJ1eS1pbi1hcHJpbC_SAQA?oc=5' rel=\"nofollow\">source<\/a>]<\/p>\n<\/div>\n<p>With the help of company information collected by GlobalData, we\u2019ve listed some of the most striking examples of companies in the U.S. and Europe that are trading below cash. When a company is trading below cash, this can attract investors looking for a bargain. However, it can also be a sign of stormy waters in store for the company. Assuming you choose the right company, buying shares of a biotech firm before the launch of a successful product has no downside. Due to an aging population and increasing rates of diabetes in developed countries all over the world, sales should keep rising. HRMY has one product on the market, WAKIX, but it&#8217;s been remarkably successful.<\/p>\n<p>This puts the biotech stock in the top 1% of all  stocks in terms of fundamental and technical measures. Its 12-month performance, measured by the Relative Strength Rating, is also in the top 4% of all stocks. Shares of Catalyst tumbled below their 50-day moving average on the Teva news, MarketSmith.com shows. But, following a strong fourth-quarter report, the biotech stock recently edged above that line. A biotechnology company uses living organisms such as bacteria or enzymes to make drugs.<\/p>\n<h2 id=\"toc-3\">Top Stocks To Invest In<\/h2>\n<p>Exelixis is a good example of a biotech seeking to capitalize and expand on a single big success. Biosimilars can improve the rate at which patented drugs are replaced by generics. CRSP is thus seen by some investors as the \u201cApple of DNA editing,\u201d but the future is unknown. It could end up like IMSAI or Cromemco, depending on how things play out. An investor is thus wise to spread their bets and be ready to bail at the first sign of failure.<\/p>\n<p>When other firms are willing to invest, you can be somewhat more confident about investing yourself. For companies who have already brought new drugs to market \u2013 keep in mind that many of these businesses need to put every cent of their profits back into research and development. Biotech companies take big risks, and they typically need massive amounts of capital during the research and development phase of their products.<\/p>\n<ul>\n<li>Its EPS is estimated to increase 17.5% year-over-year to $4.3 in 2024.<\/li>\n<li>The stock has an overall rating of B, equating to a Buy in our proprietary rating system.<\/li>\n<li>MRNA is the biggest biotech stock in the industry, with a market cap of almost $100 billion.<\/li>\n<li>While we believe the information provided herein is reliable, we do not warrant its accuracy or completeness.<\/li>\n<li>Their stock price fell at the beginning of October 2021 and is showing good potential for recovery and future growth.<\/li>\n<\/ul>\n<p>CRISPR Therapeutics takes a unique approach to drug development for the treatment of serious diseases through gene editing. The company is developing promising treatments for diseases such as cystic fibrosis, Alzheimer\u2019s, Parkinson\u2019s, hemophilia, Tay-Sachs and more. Amgen is best known for Neulasta, a drug that reduces infection risk in chemotherapy patients, Enbrel for inflammatory diseases and Prolia for osteoporosis. With this trilogy of successful drugs already on the market, the $135 billion biopharmaceutical company has solid fundamentals and steady income. In early June 2022, The FDA approved Amgen\u2019s rheumatoid arthritis treatment, RIABNI. Vertex is one of the biggest biotech stocks in terms of market cap.<\/p>\n<h2 id=\"toc-4\">Advantages of Biotech Stocks<\/h2>\n<p>In-app functionality and filters offer the possibility to arrange and customize all needed data in one place. The powerful search helps to find out everything about any biotech stock, ETF, cryptocurrency, investment idea, and collections that users like to invest in. The biotech companies we recommend looking at are Regeneron, BioNTech, Vertex, Moderna, Gilead Sciences. Even though biotech stocks are not known for paying good dividends, their growth can make up for this. For companies attempting to bring new drugs to market \u2013 has the medication successfully completed the clinical testing phase?<\/p>\n<p>Strong launches and commercialization efforts for these drugs will be crucial for Jazz to successfully diversify its portfolio. We looked for the most undervalued stocks in the Morningstar US Biotechnology Index that currently have a Morningstar Rating of 4 or 5 stars. Money management is the process of budgeting, saving, investing, spending, or otherwise overseeing the capital usage of an individual or group. A drug is a substance used to prevent or cure a disease or ailment or to alleviate its symptoms.<\/p>\n<p>The company ended up owning only half of Imbruvica, whose development could have gone sideways so many times. The biotech stock market is currently in a tough spot, with many companies facing suppressed valuations. We\u2019ve listed six public companies trading with a market cap below their cash in hand. The app allows you to create personalized collections such as the best biotech stocks, USA Fintech, or mid-cap stocks. Our analytic toolkit provides each customer with customized information and shows just the stocks they can potentially be interested in.<\/p>\n<p><img decoding=\"async\" class='aligncenter' style='display: block;margin-left:auto;margin-right:auto;' src=\"data:image\/jpeg;base64,\/9j\/4AAQSkZJRgABAQAAAQABAAD\/4gIoSUNDX1BST0ZJTEUAAQEAAAIYAAAAAAQwAABtbnRyUkdCIFhZWiAAAAAAAAAAAAAAAABhY3NwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAQAA9tYAAQAAAADTLQAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAlkZXNjAAAA8AAAAHRyWFlaAAABZAAAABRnWFlaAAABeAAAABRiWFlaAAABjAAAABRyVFJDAAABoAAAAChnVFJDAAABoAAAAChiVFJDAAABoAAAACh3dHB0AAAByAAAABRjcHJ0AAAB3AAAADxtbHVjAAAAAAAAAAEAAAAMZW5VUwAAAFgAAAAcAHMAUgBHAEIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAFhZWiAAAAAAAABvogAAOPUAAAOQWFlaIAAAAAAAAGKZAAC3hQAAGNpYWVogAAAAAAAAJKAAAA+EAAC2z3BhcmEAAAAAAAQAAAACZmYAAPKnAAANWQAAE9AAAApbAAAAAAAAAABYWVogAAAAAAAA9tYAAQAAAADTLW1sdWMAAAAAAAAAAQAAAAxlblVTAAAAIAAAABwARwBvAG8AZwBsAGUAIABJAG4AYwAuACAAMgAwADEANv\/bAEMAAwICAgICAwICAgMDAwMEBgQEBAQECAYGBQYJCAoKCQgJCQoMDwwKCw4LCQkNEQ0ODxAQERAKDBITEhATDxAQEP\/bAEMBAwMDBAMECAQECBALCQsQEBAQEBAQEBAQEBAQEBAQEBAQEBAQEBAQEBAQEBAQEBAQEBAQEBAQEBAQEBAQEBAQEP\/AABEIAMkBaQMBIgACEQEDEQH\/xAAeAAABBAMBAQEAAAAAAAAAAAAHBAUGCAECAwAJCv\/EAE0QAAEDAwIEBAQCBwMJBQgDAAECAwQABREGIQcSMUETIlFhCBRxgTKRFSNCUqGxwRYkMwlDU1RicoLR4RdjkpPxNTZEVVdzlJWistL\/xAAcAQACAgMBAQAAAAAAAAAAAAAEBgMFAAIHAQj\/xAA1EQABBAEDAwIEAwgDAQEAAAABAAIDBBEFEiEGMUETURQiYXEjMpEVM0KBobHB0QdS8CXx\/9oADAMBAAIRAxEAPwD6SOZzjFJHBk75pxWimS86isun3Izd4lIZEtfht8xwSe+Ppmj2E+EFIQwbnHAWk516MkKQG0p\/ecOP5ViPMccQOZ1J+idqcbmmM\/yFISttP4MDYj1pIltHQIAA9BW+7I5UezJy05WrdyjqnG3qcxIDfi8uNinOM5pYO1QTXGt06fvNj03b4hlTbrI5VpQN0M91E9t8bVOUZKE+uK3cxzQCfKijsRyucxhyW91sRzZPpWPWsF9CARuoj9lIya4KmOpBWISwD2Kk5\/nWmOVKSAu\/MPSsjekyLlHJ5XQtlXo4MD8+lKEnOMHY7ivSCFgIPZbV6sKJHavZ9TWL1eNY5xXicjYisch5Sa8WLBUrtWUqOd6ykEbGsqGRivVixzA9K15hkk7Drn0rOCOhFMWqbwmBHEVCwHHh5iP2U1vGwyPDB5UNiYV4y8+E1aguX6RleEleGGjsB+0fWoBrOZA0\/FS+paG3ZCuUE9TT8m4N+GuQF\/q0b5PQ0A+K9+mXvUbUVtTnhM9CNgd6ctH090sojB+ULlvVWssq1XTuGXHgKYQ5K3z4oe5uY53Nd3nlo5iobY61G7bKRZ7T87PdCUpT3PU00yNeNONqPiAJ+tXwrPLyIxwkwXIwwOmOCRlOF3vjzJKECondNUy2UEoWEn0ptu+uWnFKQ0gKP71RO5XoyiVqUB96ua1HAyQlq9qLnu2wnKeX9aXTceIAKRPavfcSUSUBaVdQajK7glWfMaRPTc7ZzVs2sweFXtjkk4kJKkUi7Q5Km5CHVsyo6wtl5tZSttQ6YIo6cI\/iObkuNaX1vObRIACY81WAl70Sr0V796q288VHKSRTVPS64kjnVjrt1oTUtEg1OIsk7+CmrpnUrGhSj0XfIe4X00bnIlMh9paFJUMgpOa1LpVtQC+FiTxBuOjX5F6Ut61xnA3DW7\/iLT3APcCjcLvbm3I7UmUlpySsttIPVagMkD6CuQX6PwcxiBzhd\/o3RdgbPjGU7RkE+YjGacWsJRkdqStJQ40CU4SK4P8AI0fLkDPrQBCPaUsflL5SELwaQqmSlp8JSyCTjPtWC9tzJHMk7Z9D71jw1qSAPxV6OO63zxwnbTFmcusstBXKlAypVEa32+Ja2Q1FQB3Kj1UfemvSdp\/RttSpwYdd8yj\/ACp4UrGR2qvlfvcfZGQs2NBQd1d5tSzl\/wDe\/wBKawQOtO2q0g6hm4\/0lM6gRtmgj3RK8o75rXYnNeO5PtWRnG4rFiwOpPrWFAms16sWLw6V6vV4isWL2cisYV++azXqxYjgrqB7VGdb6EsevLULTe218qFc7bqFFK21dMpI9tqkqlDIzWi8H6GjWOLDub3QcsMdhhjlGWnwhzFsGodF2ePaLbqL5uPFAQj55BUrkHbmFM9y1HriRPTbIbkRplwDLzCCtY9cA7UU5CSQUEDHYYpvdiNpGQgA+oFGR2NoJc0Eqpm00OGyN5a0eAU2WDT0KGluc+05ImJRy\/MyVBbpz137U+uIeW2UsbOEeU9cb9aSxCWlcqtx6GmrWLOolR4Vw0w4n5iDKDzjJ\/zrRBCk59dwaiOZHfVEgNrM+RqdWoiY4MdsqwCeYk5Uo9yT3rsI6cdKjli4i6Yv0l2C3cmWLkztIiPHw3UK7+U\/0qTIdbUnIcQQO4IrHMez8wW8c8Uwyw5WqmWHm1MSG+dtQ5SCKb7XFasb4sqpinQ6FyGELOVIbyBjPtmmzU\/ECw6ebUyl752crZuJHPOtSvfHQe5pBoG36nn3KZq3VS2UuPpDMOM0SfAa6kE9yTj8qk9NwbuceFE6YOlbHGMn+inQSCOlalI7Cuicd691PTaoAjccrkAPSuLkpCZaIYPmUgqx7Cu7pS0grzjamtxh1F3bmrV+rSyQrPY1jTl2CtXfKMpzPMO1eOewqFT+M\/DW2LkInaritLjueGtpSVc\/NnGAMZP2qY2+dGucBi5ROZTMhIWgqHKSD02NSOhkjaHOaQCoI7cMzyyNwJC6OcjDSnnSAlCSo\/aq0cQ+Ka7vqwaR0+7z3CY6W+YDIabHUmrCavYl3DTFyh2tYRLejLSwonbnxsKobwwN909qrV1+1dEfjy4ZEIIdGFFalEnGfYDp600dM1opjI9\/5h2HuSknrW5NCxkbDhh7n\/CMes9cQ9Owm7egqkuMoT+qRsp5eNh7DO5ofW5FwvtxOoNQrbjtAeIEdEpHr9PfvS223GFFsUnU11Q27KnLW4Fu7obQk4z9M5wO+Ki0i\/TLtbX78VBuKhzlipdRkOK\/0ik7cxHZJ8qRv1pyrVjHlrBz2JXLdQsfFgOsdhzhacQtSfPyBBgrV8qz0OCOb3oeTLqtoFIWQMetYu18eccWt+SpxZ3JJH8hsKic66LedwDn70xwQNijDUtthkuTOld2KeHLsvJyr+NcV3FSh1piTN5sp35hWqJuXvCChkdRRPy4RoobfCeVSio5ya5l1RHWuCFcwya2JJ2T1xUo5WmwNKypRPU70rsNiuGo7vFstsYW9JmPoZbQBuSo4FI0Ba+gyauL8FPA9bjg4q6hjqCEqKLW0pOOY\/tO\/TfA+9Vut6pFo9J07zz\/AAj3KvtB0mXWLrK0Q4zyfYKy\/D7hrB0rw4tOji2lDkKMkKcSN\/FIyo\/maCfHPTV507c7LreLBceRpyUp2ey2MlyO4AgrA7kY39jVpkq6006ijx5bbMd9hDgcVhYUMhSfQ+1cDhuyiYvfzuJJX0SaUccAij4wMBBDT2s7XqSAzMtMxEht5IWlST2pyVLSo4V9qgfE\/wCG+xMXs3fR19vWl3pJ8RBtr58IqzuC2rKah9v4R6quVyMPVPGbUsyO1t8q0huMVj3WkZq0YyOVu9p4QJe9jtjhypJrrWs6VqixcO9GvGRcZM1uTclNbiLEQeYlZ7ZIxijrpayLmyRLfQSyydvRSvSo1oXhhpnSUVu3aZtaWHJASZEhZK3nPdS1bmivFitwWUx2RhCAAMfzoKxM0fLGja0RHzOSgHAwOlYJrBUcZBrmpZJ2O9AYR25CjUa216knpB3DmKbn2OXfBpHerDcHtcXWS7PdDS5BVgHYJwNhUmiwWXo\/guI5cjyqPUGhnAh2CpW8jIUdIxketeJ7ClEiOplSkKO6SQa4NkKV\/CvFi9y5rHKMGlCkcuwrQp61ixcSkYr2MAVudjitVVixa16vV6sWI2EhRzmtSrB33FaqUAOtcn3g20pedgOpo0NyUKXYGSuTjpW4fTO30rkshXQ0D+KXxJW3SElyzaahpuVxaylxxav1LR9CR1PtVftS\/E5xRnrIXqdEIE\/4cRlKMD67mmvT+lb92MSYDW\/UpA1Tr3TaExgjJkcP+vI\/VXrIwcnrXdlZBAJ+1fO1njDxNku+O3ra8EpOf8U\/8qPHB\/4hrzKmNWrVstqY2sAIf5eV1J9+xFEX+kbdOP1A4OA9kBQ\/5IoWrLYHsLCeATgjKN940hpe+zlTjAhrmrTku8gCyP8AeG9IWtDyWElll5SG\/wB1LpxSWTd\/0DcrYJRSozHFpASf82okpP8AGp62kKTzDvS5I6WEAEpzrfD2S4tGCO+ExWrTUS2oPiNMJJ3JSgZP3p6tjyFvOx2tktpBAHTvWVtBQ37UhgYh3XxSryrTyH88iod5f3R7WtjI2qQJTjrWTW4G2DiuEouNsOuN\/iSglP1xtUGcow9iUmmK53W2OwJUr6U3TJiAolx5CB2KlAD070hsd5cuVrcussJS6ryYHTI7UNOPglztDfLRoCH1oeS46pZICB9uudtqMqVzPM1mcZKo9X1BtKo+dwyAFCNa8Mbrd9VSpj2oGxlwrQ1yJUopJ\/Z70bV2+42rh0ba3IfmSBDw0rm8NaSE9c9sVWTg7O1VprWVvmv2uKpEw+EMhS1ODODhRydvSiZx417f7PfoqdN6snWlLDZ8ZtMBLzThP7JyRkb9jTXfqzyTxU8ggDP6eFy\/RdR06tBZ1Lc5pd8pzngnlQzTkjiY1qaFHnRLpIgolpKQ5NUtHLncdd\/vTf8AF7qdyHqGHbIcZtmRIbbPlThRUrYE+pFEX4dr61qh+4jUd5fuU9hzx2vGaQylAPUhCdhj0yaFfxD6ps+sdXNxJem3WbhYJSDHuDUlstvoCvMhaCAcZGRjNGUyTqgb6X5BzjsoJQ06M6SSxva92Rk+3OFCdVi5XaXZ9CwFlEdlLbCUD\/POJGVLP+ync\/WkPEu+RLa0zpq2r\/usBAb2\/aX+0r6k0ts+qGY7N61hNDZuL5MKEANmWgMrI9yTQf1Jd3p8pbhcKionc071oS9\/zDgdvulCZzbGI2nJPJ+nsFwmzlvrwk59abJ8xm2xXJ0leENjOPWssNOPKCAkkqIAA6k1P9HfC7xJ4w3CNGEcWa0c\/KuVKBGe+yepouzZipsL5nABWenUWzTNiHZQrhZrP+11wZ4eXOzsFi8zmkNSmmh8wwonAIV3G\/Sl\/FrhjqLgtxMe0ffprMovMImRnmui2VEgEjscg\/lVpF\/DXw5+HXSbutoyLhOuMBPMu7OuJSIm2620dM+nWqdao13f+KmvJerb\/c5E9xQEeO68AF+AjZAIGw23+9L1C9+0bYkqH8IZ3fU+6bdQqQVIpI5GYcAMfZPcdZKEk711Dm4x1pMw5yN8vXalNtt9xvVzj2m1RHZEuS4ENtNJ5lKJOOgppfI2Npc84AXP2wulftaMkotfDhwnTxX1\/GtU1LgtkQfMTFoG3KDsnPua+mVktNusVtj2m2x0MxYjaWmm0jASkDAFCL4YuDg4TaEaYubSBebjh+YrG6TjZGfajMBjJ9a4b1VrLtXuu2n8NvAC730foTdIogyD8R\/JPkLoeWg58TXGqFwQ0MrVDkcSZvN4URgnZbh6E+w6mjDzAEYxVEP8oa0\/qO\/WjTbMwtckBbwST5Coq2yPz3oHQ6H7RvNhHsSrbXtSZpNM2JDxkD9VVq+fGbx31Zq0Xd\/VaorLC1Kahx0BLKAe2MHP3omcNPi11ULrHc1ahue0XE+IfDCVhOd8EVV57QGqLTcuZy0yHGygDxG0lSVfcVNNJaVv8mYyUWp9CcjKloIAH3p+\/Y2AYjHhKn7cpBnxDpm479wvr9w\/u8HUVsbv1vVzR5baFtHvykdKk6l+lCf4Z5DrnC+ChxvkSyfATv15ds0VScdcVzm7EYbDoz4KdKNhluqyeM5DhlbcwHWtCT1BrRTnXatSvY4FC4JRShV7jNm4ynElGVOebek7RCVJHN0qC6j0frmBqq9ash6iTMYD6n2raEKSotBIygHJBOx7CoTE+KHQ9wEi3WhUx67RyhtyO8wWw0pRIyokY2KT0JoKaUFxRUcZAwEYlRUPzXy8sqQpWwBpnucZuyz0BTv92eSpaVKP4cdQfzFL7LL+ZhR3883iNpUVdiTUZ4uyUC0w\/OQQ\/tg4yOU\/9Kj34GVIGZOF5zWdtU\/4Udpx4DbnGwp6ZcbmRky2D5FHBz1B9KFNseZisfNvq8yz5RRW4fFuXa31PJyy8oBOfbO4ryOTceVj49qwpHciuSsZxinCUwlmQuMDkpOwPUikKwE9R\/0qfIURGFyr1er1YvEZMY\/Ec1EuJ1+YsOlJsx54tpCMKVncDvipaojp1qtnxF6yfTNf08lCHohSjxWyem\/X\/rTNo9J120xjfuk3q3WGaPpj5ndyMD7qtUxMi93ORdZzpYiuuKW22PxKBPek8lVkiEKTCbWenMsZpfqSFMiMCXBcbmsqISgNHJB9CmoXLTdXV8klC2c7hKgRtXcK0cb2gZXy66tPLIZZTgfT6qTHUMFteRFZSCM9BUm0Wq2Xy\/26Gw0EOOSmglSDg7qFBebDlpdGHF4G3WiJwDizBrhua6HFtWyO9LUOu6U4T\/Eit9QhjjqPf7Aqwp6NFLPG5jucg\/ocq0ky7s33XseE6\/yiM6AhWdgkf+lT7VPHLhPoJKWtSa3tsd3AAaS8HHD\/AMKcmqI8RNT3ZFxky5V5kQ0OFWGI7qkLUPcg0CLhqVSnHVsNIzzHzL8yj9SaTmdHx3wySV+Ggdgus6V1HaqiSNrAXZ\/lgL6esfF3wHlko\/tj4R9XIzgB\/hUisvF\/hhrF5uNp7W1rkyXBlDPjBLivolWCa+QqdaXBp0ELQeU7DkFTKLrJmYuMqdHDRCRyuseRST67Vk\/Q1ID8GQg\/XBCs5eqNSgwZIwW\/TuvsjapZmRkk450eVQpRJIDKkkZyCKp78KHG7UTsxjTup7p+kba4gIjy3FczjZ6BKz3++9WzvbOoXS05Yn4ISAfETJSrp2KSK5zqelS6Xa9CU8eCnLR9aj1amZ4gcjghQLR8lciCuIThDUlxKvso0AuOnEu6I1WqNp2Rd2G2kFpSEOBLboOxVykHuOtEvTmuZGnZ12iXa1qeDcx0rcj4wk532Pao1q3T3B\/Xl\/ausrVM6zylJ\/WM+UJWM9goHFXWlRMrWfVnYS3HgZSV1Jalu1BBRla1+cEOOMhIeGmpG7XwyueooVtMq92pwrQJq+YlKj2VjbJ9KjB4pz+JupLdHvDVptEd1pTElZWtZbJ\/awdtu1GZzhvoaVoCbpLR17YQ9KHP8wp4FS1joFY7e1CKyfDRr1y7sfOCAw027lb4e50qT646mrOrNQc6WaRxY7PGfslfUaWsMrwVGxtla4Ddt7Zz2JH0U91NN0j8O9lFycjzrsi9oSh1+MASUHqU9gMHPWg7ZLXbOL9zuTuk9PzUlh8LbceHIktKByo9uuB70S\/iIsGqbZa7LCtzD0u0QYwZUpDIc\/WeqgQdqivBG0azhXZeoXHTbrKxyNOlaQ0h\/myOTlxuRU9Jwjqm8JMyHyT39uEHqtf1bjNHNYtiZ\/18cZPPbug7xZtcTSCzZYsjn8NCS4UnIKyN8UHkv+O7gq70QOOs5SdYXCGjmCESnEhKs5AztQ9itHZSBuroKf6O4wMLu5Cqa1ZkDXEeScfqkF61E7ZXmjEc5HkEOBWd0kHajj8PPxhX22X5Fq19eFv2t0hsuqSkKbA6E+tVn15a76JrrhhKSMeUJydqh9ih3V98peKk5VuKrr8cV13oTM3Aj9E86XWhjrieN4yOcq2\/xWfEhO4p3JXDrR11DumozgcefaJAkr7J+goSWG2JiNoKQdhvTTZLSmOAogBXSpUxhpIORROnafDQjDIxhU+s6k+27aE4RIkidJZhQmVuvvrS22hAyVKJwBX0V+Gb4b7NwxscXUmoIjUrU0toLWtxORGSrB5EZ6EdzVdvhM4TKk6hjcQNRRkqYinxILLichSuyyPT0r6AMuFTbaiOUlIyPSue9aa4+R4pQH5R3Pv9E59D9PMjYbtkAuPYe31XcK5dtq3bWehrlnPShzxY486C4QWxUzUt3ZbfOzcfnHOo\/TNIUFaS08RRNyT7Lo8kzIWl0hRKcVjtivn18ZWqLbI45uWJyU2l+Lbo4CVHGQrJorPfGTp1DT9yvstMaM2C4222r8ScZAz3Jr5v\/E1xvY4ycUJmurc2\/D8iGUJChnCBgHI9qeOmtOtaNdFmw3gAj9Uo9SRQdQUTTjcRyDn7KxFlUgNJQAnbbGafUFltBUpxKduvQAVSvTHFbW9vV4SL6vwj0Liubb71NoGutR6hmoZuuoZSI\/OMtJJAKfU4IGK6Y\/VIpWF7RgriVn\/ju38RtdKNq+vnAeG3D4XWfkwQ8gu5HQ5NTxasjp0oK8IeLmi4vD6wxGrmyuMzFbY50n8KgADmjBFnRZ8dEuJIQ805ulaDkGuF6lFK20+SQYBJ7r6K0dkVelHWjOdjQP0XVbnbG4rQrODmtVqAUT71xW4Tk4oIBHl3OCoxcXOW4yN+iu9VH0RweiXLjJrHXUtlK7RHuT0ViP8AsPOZ51E47IKsfX6VZfiJqm26Stl2v1zkJZYitLWpSjjtsB7mkWntMotmk4L7TKUoebMySpPd11RccUr3KlGqx8fqPP0Rok2NGPKURLrarTaoonLahNuL8GMnB82BnAqA8SGNSXqd4ybU63ZobYLcgkfrVHdSinqAAAB96lFzlM3i5RIwbyzAHOUkbc6ugz9B\/GpYVMXCEqOpKORSeQox6jGMUOR6gIRAIaQQgfbtOy5a2\/FOGsDGDnI9qL2nWP0bCbQUeGlCcIR\/WgvpPhNxGtesbmuz6jQuwqlKU3EkSHf1G+cI6gD26VNLrrPVEG8yNKSNJzI08gJjTVuJXFkZH40kHmxuMggHNeRfIDlevJee6xctcQpt+uC7dLC37U+GHQD+FYGd6lUSbF1BaU3qCkJWnCZLQP4Vev0oDM6LvGgNQyZc2Q7cXbq\/zTXUp5U5UfxcvsT+VFbRiH7NNU+tZUy8PDeaPQpPtXsRcX\/ReSNaGhPfNXub2rZ9KEPrS2rmQCeU+o7VpRSGRfeeDTK3CrASkmqMcYtVou+rp76JAQ624poJKgOYA4xVzb7LdTa5QZOVFpWPrivl3xouF4OoJ62FqQ9IdKVIxso5wFJ9+xrpXRkQbM6U+FyT\/kSH4+CKpuxk5Us\/Shhy0yXoywoEEcqiAcd9q1u2pWLm+26qO4VpTynmPYe9V9uOvtYtsfoyVIWkIIxzJIUMDpmmN7WF+SSf0g6k4IyCa6ULtdp3OHIXPIukJXt2ukGEeZ+ooLLh8VTDeD+0oUTuEeoYVu0lqXV0dbTjzSUREDGxSrc79+gqi0643KdM5VynlqUdvMdzVhLPcZ+kOH8KAhK\/742VSUdynPX7YzUNu0NQi9BgxyFbx9PRaQWTB2XYK7amZk6uurs2yOuSnHuZTrCkkuNY64H7SfQihs9pO5IfeQ\/Heb85BDwLe\/0O9SixardsU79I2+V4T+MBexOD23p9f4rM365W8aiVbXEMPOJWlxjy8pRso4O+4x\/Gj44JIm5Iy0fqtq3qBxEYOShq1o5La+Z1DH3Wo1JI2m2XI8fkiIK8jdDp\/kRTZxD1jFlTYsuyCKG1sBKkR0FHKQe46flSa06quKbehQHKUKJzU7Y4tuQCCVNchvOYHZCk9k1Fd9A6mEhMl5mMD4nKFbEjpn719Ofh64xROK\/CyDfPHQbjHHysxGfMFp749xvXySvuo5t2yHFkoH4qP\/wWa5asusFWG83KVGst5cbaUth9TRQ9vyKyD07H60odV6Gy9U9Vg+dvP1wrnQbkmlPEkvZ3B9vorRahdDGoNRRysJKpZIB753oNcS0ToF1jOqfjAuN8zSD2SFEYz60SNUW6VbuIF\/agXFamY7iXE\/MfrecFI6k75qLXfUNouLrTep7DBlFgFbS8cp2PYGqXS98Za5oyMDhJXUhgsSvZM7adxx5BUZtF8vFqgPrXNILvmy2SOU9gDSyx8Yta2s+BDvFwdWlQBSsEgJzT61cdDXxhcVSPlUY5VIKAAPeu9i4T224zG0W7UbskPqAaZTjmUOwz6VYyT1Q1xsxY+4VLToag2Rooz7iTwAcf0RN0dxE1rq64QYUFht6G4OeW6+n\/AAmx+IntmmbiZq2dqDUsKPa0eDYLbMQgco5Q+6FAk7bEbVPk6Ze0\/ZBofSSGzcpiB87J7Np\/dyN9qgGtdLL0LZ7bYpVzTNkfMLeDo8uckk7egzShDJXksbowAPA\/uV1ptW\/To7LLi5+Mk+AfYf5VTuPcliXxAus2KCGn3ytII6ZAzUQ02WzdYIdICFPoSokZABUBmprxf09LRKXdC6H0rUStSNwnPTeoHan5FvkMXQwlvtRHUrKUjIJzt12rq1eWNlMbD4SBHumZl4wSTlGbiXpiNpm2LuM6fAnxnB4TJSgBf3qvDcFh6Yt6O0EJKsjAoh6u1mvWDDcOFClOqWo87b3IkBRHUBPpSOz6Pei8jl4aXHZB6KG6vaotPfmPMhyQvGmPTWH+Eu\/hzlNdo05crosogRVuBP4lpGyfqasBwl+Hu3z0MX\/Vc\/5hptQWIjQ8qj\/tE9foKbdMarsyWv0HHskREdCQT4OylH3Pejhw2lFNmDaIhcjE8owvCken1pf1\/VLcLCGDaFedNCrqFva85IGcYIRV4eWpszI0SK2ltorACUjAS2nsBRs2HlSOlB7h8XPnE8qSFDCE4P50StSahhaV0\/P1BcXAmPb4633FZ7JBP9P41yu4DLKAOTldppBsMGfACGPxIfETp3gjppxT8lKrtJbV8swCCcfvEdq+S\/EXXuqeO3ENoSn5s6VMdwxHSvZGT1p6+IzjNduLWv7lfpshfgKdUiO3zHCGgfKB9qG+rrrbrJqeNN0XOeiqhwow+ZjuFtZf8IFwhSTkeYkfauwdOaCzSqzTj8Vwzn2S5ZuOvTkn8oRg4u8LrDwk0Zbol710iZqyT+tetkd3xWojeNgs9So1XV63Inlb4UUqJPSud0vk26SlzrnNekyHDzLdeWVrUfUknJraNd47bARg5Gc+9Mtakww+naO488\/6UJjez54xyuMeDNaX4CFIUkHO9P0f55LKnDIKFoAICehxTXEmIedUsZx2p2ZfJHLjII3rGaPSjO4f3UNiWTOCFOLJxz1poy1NM2jw1BCgcryQB9Ks38HnxwXlOohoziE6FxpzpMd7OyMn8P1FUgTK5HXIzu6emD3FcY3zdsnt3W2LUPllpdQpPVJBzQGp6RWvxGNzRg\/qpq0hi5PBX6A401idFbmxnUuNPpC0KB2Uk96wte56iq0\/BNxjd4haBRZblJ8SZAbSpHMrcoPUfY1ZEnmzg1w\/UKL9Psvgf3BTRWmE8YeEPeIujdO61tsyzahgIlx1r5wlX7KxuFD3B3oX6b4rqtzMvhhd2pD16gy24cXCTiUyr8K8+yev0NG+6NhTz2e5oDOt3C18a5V7Z0383GYZQ34\/MBhxSf2R3IB\/jS7I7Y\/KumM3swioq0ORAAppXiOeYkikrl\/jRpJix3PF+VHMvHVSvSoVxW4k6yTEY0tpG1Ki3O4DImSkHwmEE4JTj8SvbpUKskfUNi1e3b9Q6oXPL8YAtIjBtpD2QVKKslSlEd9h7VDZkbw1ikgiIGXI4R9SvxY39yZQl1zzOKVvhRr1uemX+4MImBLxYV4iVqH4PpTfHgeGwlalApIBJBrsrVlm003yLILyz5Wm91qPqa2EbgMlaucN3yp0utkjXVSTIZSpaTyqBHWkMhhtp9YSkZSSnP0pfGvTDzRnBwKU4OYDvk02LcUpXMrcnc1I0YC0c4nhYUvHStsj96ue25NY5k+9bLzaiNLJW2seoPeqQfE5wwVEvRubALMeY7zsugYQh3uknsavE4nn+lRDW2koeoLe9AnRESI7ycLQpORTpoepHTZw7we4SB1No51SuNhw9vIP\/vdfLvV2kNWuNoiTrWha2ztIbTkqGNt+4qHOcN9TOEFNudXn0SatLxK0PqrRlyci2x4uREkllEgZAB7BVQprUOoYaCmbpk8wOy2fMDXVIXw2mB4PBXIP2xqVLMW1u4eDwhHpfhHf3tRQTMtrqGQ8hSyobcoOT1ok8XINyt7keda2\/wC7tpCBydE+oNSjT2prjPuqGZFpcYb5FEqUDtgVveJCX0OB5JcbUd0kfxouGuwu+VV1nqK8bMbpwOPAVbplyLklTzUdMZRHmSnPLn1A7Uyz7g8mQVqCFZ9RR1m6LtNxCnWobXNk7A4NRO7aBtGSHI6gpB3HNV1FE\/OGnlNVPX6ryC5pCFirm8sYPIn3pztzj78fl8RTnoE9BUua0bYWykqhhRz3Uak9qtVrgMJSzFbST6DepXwSk5cUXc1yu1mI2klQWxaVuV3WGlpUy0o+ZSh29qJWmbTH0wAGyQWjzBWd+bsa80pDTnOCEgUluV7jtBSecKUrtmtDC1gJcM5S3avWdReI2cN47Kw2keIStTplXC4qSl+S00wpalbEoHLkn3xXtSaJGokF39I\/LKQgFjwjzAnO4Pp6ioT8N+o4cK8OW+\/R2nIU9HhoQ6kKTz522NWWfsmmSvmZs7THoWso\/lXNtRl\/ZdssY3A8I+v0+NWhLzLyD\/MFV6Gkl6alBpUt+UXAAokHcnoAKsRwe0PcNCWVGrdUth29TU8lqh9VR2ldFKH7xyBXfTtm06xeGri\/BVKMc86WnTzJ5h0O9FfTUFu5PuatuhQtaSUsNno1jv8AlS7rOtvsR+g0YHn\/AEmTpfoltOw69YeHP\/h+n1XrXCRo+xv3i9upM+Tl1453Rnogf1qtfFi4Tb+1c9YTnHkQ4LSkMeH151bJx9yKJ\/EnVc3Uk6Tb7Wr+6wW1LdIOAoiq0am+JSwzX5OhGuH18et4cEV+UFFBKs7rCCMFIxQOlwubJ6pGT5+yaNYcJojBGcAA4+6AE22vmeuQV3NUZ10OFBfVyE5ydiP61YK\/jS1y4aW+dY7U3Dc8RoOI5RhRwQc\/enyxcC9DXO1NXtnU8l9gg+JFXyJ8Jed0lRO1R\/i7Z2LXaI8LT76E2uMpDXLHWFYcOdzjr0O9OjLME0rI4CQQfPZc6vxW21i6cAg8Aj+6imkLHCcvTCFR0Bvm53ClvrUv1Bp9994pgymlt8xVyrGNsdCKG+kYGp06gRMskmVIMYFwK3HKkDJJrab8Rl0iXssXLQz8zfk8ZDmMjpkHG\/0NFWpnxzAsKpa+ifGxnJy4dj9P5qXM2CXamV3D9HHH4FLSnYYo58L31o02lzf8WcEe1RDQ2l39ZQ1ajsVwC4Mto5gyVcq2V4zj3qf6C0VejBVD+ZfirbUvxGkAKBApf1i4LcZY48hNHSGkPo2zNg8jvnvhGDh4ktoTJIwrBV9zQ\/8Ajk169pTgLPRFd5HrtIbhdf2SCpX\/APWiXo9sRbWARg55Rkb7bVW\/\/KLree4SWnwyeVNzyrH\/ANteKWtLiZY1OMHtldVsvMdNxHsvmTc5K3H1rz1JNR+S8sZUo7E5FONxWpCiN8Gm4NiSnBVuP2e5rtz5QwcHCpqrAG5Ta7I5ic1r44AAxU61Lwd11Y9IW\/Xty0zMiWW5AfLS3G8Nu+n50PXQ6kKChjlOKrhfa\/5mHIVuxrXDCdLbNShzlUTv0qSMSARgGofAaSpaVkHbrUjjqzjAxUzLpKAtQtL8hdrm0+SiUzvyjCsV3tUtCzgHr27H2ro0sbA7+oNIJUcwpqVtApae3AHQGpWS7uShnN3twe4VxPgP1g7YuJEG2od5GJxVHUknbfp\/Gvp2heUkg96+SHwhh\/8A7VdOcgJUJaFH86+s6Hf6GuYdbRtF1r2+QrPRnn0nD2KHV84pW2LerpZmbDqOTMgrCCEWSSGFk4wUvlHhKG++FH6VvZLY5JSzcpiSHH0B5wKGCFK3II9s4+1LLrkXiSQMZWcbkU5WtLSGTlCAvlJ2PWuaSxkP5KbopAWgYTPqu2wn2oEl5tJVGkDkOB3B2qPwrLaXZ7sqRGS648OVRUOgPpW3ES46gXItsSxWKZNbQ948h5pAKGwNsHJ9z+VaWW6RJryTHeB82Ck7KB9COxqA8uwimg7eF1uEN+E69AgyHUMISPDBVkgfU70xRLURJ51oBWT5lK3J+9Tu42uQppU1KUrTjzAdQKbGoo5eYAf1oodkJ2XNlCWkAYG1dOYYzmsuJ5cjGK48w6VixdObPoKzze4rjnevZHpWL1FhTYSK4uIC0Y5falbn4s1zUmrbKpFD9UaGs2p4qo9whIXtjcb0ILx8N9kdeKo78hhOeiVbVYzlTnBpFLYQUkgDuasqmp2aoxG7Cpr+hUNQdvniBPvhU215w9iaBfPyzzrynGQCHN8knfH2oK3u5PwH1ocbKmFHI9U\/9asB8T9xnQ7m\/FgOKQ8mKHEEd8Heqk3DiJdGkKccYamsg4dbdT50H3x29667oVt3wrJJznK4lqGkNl1WaOq0bWHGCnJepGwolsqAB69xSV++RniSpWSeuTSNrWOjZ8BTqonhSUAlaOblB+majjvEDTDaiU2V1Q9FLplbqdUc5REOjyvJxEQQn125wEryDt9aSOal5TysoUojYbUwvcTLKkHwNLpJ7Fazio\/O4sXAOqTAs0KPy9MJ5j\/GtZNartHB\/orqvoE0vDmfqVOXLle7ifCiRHPN7Vyb\/RFskFeprlyqTuWW\/Mv\/AKUOZPEHVVzYw9cnGh+615B\/CmxuRIfcLzry1qV1Uo5NVFjXQ4ERtVpHoHptIeQPt\/tWM05re0T1FFmirj\/J8rzbi1eY8p9BV9tMPIvOnbdcilK\/mIzbhIGdynevmVw6tc9yLIltoOCjlG3XNfR7g6t1rR9qhP7lqM2nf\/dpW6m3SQRyu75WmhQw1bssEP5f8qZt2BZt0i6NthDbAG4HXJpNcdS3BqxJ05aEK+akOqKlfupIqR3C9SI2n3reIzRZI\/HnBG9MemmrZdY8qSxLbEtba20DO6DggH8653uLnZeMhPzmsZFtiOCQqsap46cUrVMv2loGgbOtCCqMiauWtLgI2JOFAJwaZWeBXFbiExF1NHegfKzm0Kf\/AL8cBYSApRQB\/wCtMGteF3Gu16okw5GmLnPKn1FqQy0XUuJKtiFDp96MVhj604IcGZL+rrwq23rUMzFriugLDWGznmHvnJHtTg4xVY2\/CuBeccfdIoFizKReYWsbnJ7fZQXjVwkOmNFWyzKulzmOoaXJfdiLCUpdz0IP7NQrgdqRjR98Zt6YHz8eetDLrEo+L4mTglKegP0ruxrLiBddTWmFxH1\/CuUQvcqkxwlaUtK2VukDl27GrY6Q4U8GdHvt6gskeEpSk\/q5kyUnCT1wnmOAakmsNqQ4sNLnu8haR0pLchjrvAjbjhRHilrTQvC1sRZdmlRzKRzEWyEhxaUnuQSMCgZpfTEHivJnSNKWaRLlw5CfCW9GEcqZUCSVjONlYx171tx90\/qr+10qS9b7jcWZa1ONyY6FuoSCdkgpBGMYp34W6e4p6H0tdtYWtpy2olBplpVxBT4zishOQrcJHT71LDH8LXD45AXHweShpyLj9s8ZaBnkcDCLkOw3rhXw1lyZJMie62PG8JfkjpSOx9hQPk8Q+OOm79Du9n4nTJMa5OeJ8kU58Nv9xaOXHTuCK3tvGXidNvn9muIci3y7WslmWwxy5AV15Ck+arEs8BNBzIlv1TBvMlyI402ppCiN0jcj+FQFzKbS+6NzndsDhSl1l8ra+kkbWjkE9vqiVZdcWyz6YtatRXCNHkORkOuvOr8NAyN8575oWfFSIvE\/hPc7PppIujkfknRHoa0vJd5dlJwkkhQCs4PbpUW+Iu1G4OW23RIabpAKQH0KJIaT0TjHoeu+abfhh0ujTutZ0tmKqHDis+O95lFrmBxk52Bws9PSq6GkK7Pjm9wcgK\/fr+2dmnyjJPnlUAkaD1fdFOKhadnLTHXyOEtFAQr0JOBn2okfCz8Nd\/4v8XGLNebVKiafs2J94feQUBLST5Wwe5Wdtu2T2q0PG3Vd44ga\/b0Pov8AR0mDLkhRjTIvKHnSAPxDce3rmrH6O4ezuEvC46Z0hbo8i+SECTMSV8qC4rqgKOTyJycD2qz1TqCwyttIAe4K40yaOy8iLlrfKrB\/lKbxHtnDLT+n7O0iJbo89LMeO2MIQhKNgAK+bcyWHGyeYFW2Nt6v3\/lK03D+zGlG1sOnMt5x0hJKQQkDc9q+fLzMhxI5EkjNCaVYdHVDWK5EbSQ5OUF4pSMgGnWPMwQM4qPMqlJAHy6tqVNKmKPlaAHqo1cQ33t7oeaDdnClUVZWsebIpeoIkIbbKclKgQaj8FTrYHnyTUr09DE+S2hQUSpQHLjqavKuoRPHzHCqLEMgOG8q1fwM6RduPEeNc1JPgwEF5Rx0PavpIHgQexqs\/wAIvDdWiNEJvMxjw5d1AWAeqWx0\/OrCtyCTurrXOeo7bbtwub2HAVtpsXow\/N3KZJ6mET5S3ElSuc4yo+lIo0C3OvKklEhD7gxztSXEED\/hUB\/ChnrXV2pLDqm6KgykS46Xslh0fg26AjtSjhjxLka+FwYcDNum22R4bjJJUSkgFKx7HcfVJpOkAeSAmKMOY0OKMzSGI0RCUA8uOh3P1J9agVx0rZrfr3+1cNhDb9wj8roAwFOJIHOfflIH2p9k3d+KwWn5aXSkdQnlqKTLu5cry1JjS46moTLjTzfNlaXVFJGR22Gd\/WgTGScBHx5xuKIUSaD+pO6VDBGetRDTl4kT1EllIStaktIz5igEjnPoDimm5ayasMB67yg4tpgJHK2kqUpSiAAAPcikel72Wprjshf+IkBOdsbjI9q1LtvAWxhzyiPPs6zFVLYdC+QZUgDoPb1qPFeCQakNouiJDgbWsFLg5T9D1qKOOhLikA9CQKlHZQuaRwlPN6VnnNJA9itvGPvXq8RoWo5BrUqB71gnIFaqVirXOeypVhw4yqkUleEkYz\/Su7jmds0lf3Qd62Y3laOVbviM06ufOhXphJ5UZYfHqg1SrifoWfa5Dk+KlaW3MhK0Zwr2OOhr6NcR7Gi72x+M4jIWk4I6g9jVTbxEk224v6f1E0lQWcsrcT5XU+mexrq3TFoWKorv7jsuJdVssaNqp1CAZY7uFUefZZ1vB+aiLR\/tAZH502Lb9SD7GrT3DhtZLk2tkOONtOblBwcH2ob37gZcm5B\/RjqHWCdio8pT9aZW1D2C10\/rClYO2V20\/VBrwxjYfwpnmNq+Y2bOPpR9g8EbmsBEqRGbAGMkZNK0cCLa3JDtznqcAwQhtOM\/esNBz+Oys2dYaZA45fn7KvkGE\/KX4TbKlKV023qeaT4a3e7Sm0y2FMxk4K1nbAo32Xh5p+zuh6NAQtwdDjOKfZrTcJtKVNAur\/w2EDdXucdB9a3bpcUfzSclUl\/rh1gmKkzGfJ8fVNOj4UGPNb0\/bmAlLXIg5G6hnqaupw8t6mbYylQxhAoAcEeGjd1kPX24O4WhwFRKfxHrt7Va\/T1rbjwkBsjlAxnFI3VV9kjvTZ4V90bRe6R1t3Id\/X3KU3CAF2OW65jCWzyjPeqacR75qPTt\/df05d5EJ9DqlksnYj3HQirk3+Fz2qS43IeRyNKJCFbK271U\/UjWk595kJut3TBlurUkB4eRftmlfS3fMS7kJs1pu+MNYcOSTQ3xs6j0\/ITb9ZW5q5x0eVT7WEOD6p6GjBqzUPBj4q9HR7P+n1W+fEWJEVz8LjDpGN0k4UkjYj2qqGq\/hsv8y4qudlu0dUN9XMCMqCR9RTdqDSjvC2wNPF1cmTIdCHn05SGxjbHpuKvjSp2JGvgOx49lQftG7Uh9OYeo09wf9qwelPggTEvUe433WKbhBjq5iyxH8PxRnOFK5jgfSgj8RlpcRxAmwLk3OaiWtRaixvF5WkN77hOOp28w9q66K+LDXWjJMeJCuTlxjHGWJB5hj0CutHhPGHg1xVU1D4m6bahysJHjOoynfBxzDcD61KY7tacyWR6rAPHcLHSUpYmthPoPPv5UL+HrjNctG2OXERp2TMsVvheK4UkurbUCcAKUOp9KRj4r4vFKWnR2odFzINquDxbMhUhDhaJPkUUJQkpAON8n71ZeXoXRl34aT9M8Ok21pidHKWwzjCz1GSKpg9wc4tQtXIt7ei7it5S0p5gkeER2PNnpUNR1K7K+R42EdgVvdit04fQYDKHAnPj7ItRvhJ1DcrtGvDeqbU1aXQh1MppBKyDv+HGM\/euvxQS5um7Da+FdokSWbezbgtMtl3kddUpXm8w+h296U8TbjxY4P6EseltPX6HHuz6FOuB1QPhpzkpSVeUH61CuHWuZetLxDs3H1qLdmLg8G4UlpafFaKspyvkO24\/jUkb7E7xPMQ+NmcAf3Qb4q9avsr\/hzHGc\/wBlD\/hrRf7HxQt9sdudxdgS3UtvxnFlaVjOQdyd\/sKt1xA428GeGlzdsd8vEe3yZCVhbaY6lqWOmcJB8uf5VrY+GXDHhdqFd3Ymw4kl1KkMqlSkAjb9nnI3oHQ+EauIPGZi0aohtT7Ytbspc5zPkbCslIWNgo56Z3zkUHYdWvPM3LWNHk91aVXW6RbHMA57z3H8IRO4FcI7NL11cPiFVeBcotzTy2aPg8iSRguDOPTAyNqOMRq5W5Vyu14kpIkLHy7IH+EkDH3J6\/lS6xwLXbkR7RZ4zce22tkMR2k7JSEjFNF0luX66CDGUSwyfMfU0rWLLrMhc77D7J4rVWQRhjAmHUf9lVaWut519Bt8myssrdkImspcbCAD2UDuelfGLXK7DcNY3q46ct7UG1yJzzkKM2MJaZKjypHtjtX0Y+PF3idddHR9K6HsEx7T6P1t1lRTzElPRBSN+UdSa+b0myT0LIUwvPpg0\/8ASVaGGB08rdxPj2HhB27Aa\/ZnCaxEWr8BxmsKafYIDjQINOLNruYXhpl1XsEmpHaNE6qvBDSbWsI7qcASB+dMlmOlKwkN2OQwslp4IITHbLct1QODnPQVbj4V\/h4f1JPY1bqeKpq1xVhSEKHmkKGCAPah7oHhPGtMtibeXUyXAQQ2PwD\/AJ1efhtNaRaIzDCQhKUAJSkYAHpSfecYmkxqYS73BqLVt8JlhEdhCW220hKEp6ADtTswo7Uw25SlAYp+jpIxilKUHyrGM5QG4hxVydTXPwlFKvEO4+goUm1Xaz3s3+yXl6BPA8NS2wkhac\/hUlQII+oo3asjpGp7i4pPVw9vaoxJscXzTpighCPMd+1LEjsSFN8AaIhn2SMay1w9YXHpcxh1aE4S58uAr3PXH8KEOi35s3inIuAuE9lqCgOy\/CkKR8w6s4QHMEcwwFHB22FHvTdpGqLf4jKVNQXiUtEdVgbc2\/ampPAa16UfvWobVfZUuTN8N1xh5CeVAbCtkkDP7R6+lROc4HIWwDXcBFKzz40aC2otgrWkKwoA70OuMWs7fpG52iethaGrqpbLi22yoIdSAUkgdARnJ9qkGkLjHvEZhZeGCkADO52pVrrTke5xUuQbu9CmoSSwoNBxCFYICyD6ZPesadx5UsbNr9gUetfFG0aesbuodUXNi2RUoOFyFcufTlHU\/agvrn42bFbFqi6DsLl1WU+WXNy20o\/7LYAUofUp+9BX4g+GHEGx6pjz9U6tlaiiXDmEaWry8ix1b8MHCduntUBbRZrUBHmS1Ovg7sRx4jn5jyj881dUtPZMN8hwE96L0lVtsFmy\/g+FML58TPG+9vOKOrJ0RtaytKIKQwGx6AoAUR9ST7mmn\/t24y\/\/AFF1n\/8AtX\/\/APVMr7zpbHy1kaZKjhK5T2VH08qa1\/QmqP8AVYX\/AJf\/AFo00IB2ymd3T2nR\/LHHkfy\/2vtjnO+a0UrIrXxBjr1rUuDGxoUDC+b8rVfKc1wdBI2rsTnvmuZ3OK3HC1cma7W9EppaSOooGcUeGzd4YczHC8Anp\/L0qwjyE4z601TrbHlNqQtAJUO9Wun6hJSkD2FUGs6RFqkJjk\/kqLvfpHTr3yMtgyWmjygKPK6kfXor712RfrEpP69+VGV\/3jJP8RkVY\/XnCKBf21vMspS8B+IDFA28cHdVW99aYxDie1dLodQ1rDPndgriWrdE3K8n5N49xwVHzfdMIIJvAPtyKz\/Kk0vU+nlEiMzLmKHTkZIB+5pf\/wBmusyrH6OTt3xTrbeD2rZykiRysAnsKsH6zWYMmRVUPSthzgBA7P1P+goh+lLtLOIkJu3tq25lK8Rz7dhU74d8JZ2o3U3Kcl1qETlbxBLj3sKJvDDgTYRe46b\/ACPFWfwoX0KuwowXe3X3T93as9ptnJGbCfCS2xs4PypV1jqxod6NYZyO5T7oPQMko9a5hrf+o8\/dRWw2D9FR2INpiJbaRhCQQd98b1OrzOjaSS1AXEMiQUhxXmKQPpSXi7eIeiNJPXUsttXJEFcnkT1BQAScexqDcLvih0XxX0tHul70uXpLX6tSkKBSvHU74I6dKSpXT3W+uG5C6VVq19PJiJ2kD24+ynWoZrZ0eu9oC2mX0lBSdyCdhg\/WqIcY2XJ14fiMpOAolSsbE46Ue\/iF+KG3QLzpzRVkiJjIkSEKXHRvlHTzegoYazvDLN0cbVCZlMr8ygsdMjqFVZ6fBLXYC9uCVXasWSv2NOcKvFq4l664fz3P0LdZCGml8pYWOdpXsUqyB9qLVg476M11bV2riXplMPnThchjztqz3KOo+1cp2ldH6maW02tqHIdIPI90UfZY\/rUN1XwtvFpglMeAUJBBSpG6Vp+oq6\/BkIBGClxzZomYIyEVbPwa4cXNBvWhnIdxQPMOR4qUj\/hJ2oU8QtMay05d5Batz7sdefDWEcwHtUKiwdZaXuSJFnuEqK8nBSphRT+dFmwfEddYIRbNd22NeWEpCVOYDbyCO+R1+9Fx\/EwE7TuCBfFUneH4wf1Cb+Gt84kaJhyNQMXeTbGEIyEK3SpRP7po5aI+NJVtWzG1tb230KwkymSM\/Up\/5Go7En8MuLNqfgafvjcaS8jlMKUfDcB\/2Sdj9jQ1uHw2aig3VKZtxCY3NkKKDkp\/lUcj6dxhbZZgr2A3aEvqRSED2HZW011H4cfEdaIUqz6lbi3BlBUw4DzZB6pUkkGozwl+Dr9EahZverNQpmx4kgSWY0dvlS4objmJOcZ9OtVs1nIVw7l26Db3HWAy1+rfQopUT36VNOE3xa69tN4YtEl5VziLWG+Vz8afcHvQ8lC3DW9OjL8p8H\/BRNbU6lqb4nUIMEd3DsceSFHviTs8TVHE28yb9Jm2+VAeW01HUC42Wwo4OMgjbfait8KV2chQJeioj702CwluWiQ7zcwUpeMYJOMjG2e1S6TrHgVxmuJZ1lbGYV2SfCW66Cgr\/wCMbH86KkDSeitFaYgwdItRG2XX0uKU1grcAGxJ6mqy7ZbDU9B8RD\/c9lb6ZA+1cbPFOHRg5A8qXTp6LfZ24kRX94kbEjqKQSHE6bs3MVZlyNkeoPc1ys\/hSpK7jLX+qZG2famK83M3m5LcUrlaSMIB25Uilhse5yd3vLRlRHiNqxzT+kZiGEhyXcGlsNDP7wwVH6VSqToRPzePAClOK6Y6kmrj640wbvHNxEkKDWEJbPYe1A\/VFrRbZRC048MZBx3p70JrQ0MaeT3SN1Hqx04GV\/2CHbegmbUopuPy0cg9CQT+QpwRCtrKR4crmxsMINd5MmQ+omNFBJ3K17k1w8G6FeVBGPTpTJJVL24JSJH1dKH7pD\/VOsGzSlcj7LYW0DupJz+dWB4Xx5HyTKVIOMCglpi5SILoSUJVnq2roofWjhw81LbYkiM4lfLb5LgYWhX44j56A\/7J7GlzU6sjGEgJo0bqmC5O2Mnv7\/8AuUabTGCUpyB0p+aawAQmksOOAkEDsDTk2kADbcUjyOLuSumMGAgnrNPLqOeM4y7\/AMqgHE66LhaakIaXha8Nj77f1qc6+khvUdxGM4c2\/Kg3xRujcqzrYU5yL9D60tSkeoU2xgmJuPZHvTzcaz6Wt7cVCW0oitJSB0HlBpluupERg8XHgAUKzk9sVCuHXGzRt\/0axaLtqOBAvEFpLLrUt9LRUpOwKSogKBHpQp4+8XIejLHIdE9hc2U2puG0hwKU4sjYgD9n36V68ZII7KegwuyHDlcvg74i3bVOudY2SdPMiFYpCkQj3wt1eQfoBgVYTU+qYzMx9rxUlwKKQkHoBsK+V2gNd6o4aXp+8wp0hpNyOJSmiRzHJIJx7k1aXS3GmyXjTzd3uVyQzIT+rfDylBRV2UM9cj0qeNgc1X+naYJZzI9yk\/xLy277opi388hb6pzRZaYyVLJyCNvY1XKHAt1pUGJD6kPoVhcKByuP4787ysoa\/iR6GnbirxXt+qZbMG13GU9GjglbcXKVOqO2Cr9kChfNudzlNlny2+Ek7ttbZ+p6mrBk5gGI06V5zWb6UHb3U0uerrbHLsHTVhhNSnSEmRkyXWQP++X+17oSkUw+Fdv\/AJo7\/wCeaYo7qxiNDSpAUM83RSh\/QV2+QX\/p4\/8A59QOc6Q7nEkqYbpOTkr7unA2B6VhRziufPjfFZznei187rx2PWsEDc5rxyTgHrWeU9Ca3C0c4BcXNxjFJnEe1LFJA3rgtJPetlrkOSBxgKSQSaapdoZdJ\/Vj8qflIxn+FQniXxHtXD20LmvRXbhMO7UOOfOR3Uo9AkdSaIrRySv2Rd0HdsV6sfqWCA36rWbEjw3Wmw22VuKwEnYke1JnZEULWzECQpBw5nqmqzQPiWu0rii1EhtuXhNwdS06lpGW4jR2\/V+47mrJWS1MTLw3LVIAdcbKXAejiR0+4\/rVlJAa\/wC8KrGzCcgsHf8AsoDxt11P4Z6Ef1lBiqfdhuoUhsKKSrzDJHuBXK0f5QLThskZ+VqOMy+40Cpl9jLqTjcZ70u+LXT7ErhOsBOzMptZGO3SvnPcdHNqlrcZdCUhRKQR+E0waT04Ncq+uBkg4Q0urx6ZYNdxxxlHjip8VGp+JHEfFpfU9bnYb8NSnE7OIUk527Cq8Wt7U2nkyG7NIkMeI6onwXlozn1wd6lWlLXHt1yiFRU84VkFR2z5TTfbJSZ0p9iGhbjiVkFCUEqG\/wBKe6GgVa0Xw0+AQqmfVpHvdPAMt+qcNGi7TdQwrhdkEutvtlC1nmIOdzk7n71ejUGiIM2I28uMjzNpJKU47VSy1sXKLNjuvQnk8riT50FI2Pqav7aZ0e7WOE8jlIXHbOxzvyiqDqmvFSbE2A5A8oejYfele6Q8+3sgRe+G7iVKXDURjtimeE9qnTSjHQ4tTCtlNOJ521D6HpVhZlqbdBIxv7Uxz9OMPJIW2kj3TSqLQIw5WXw7geEIXY+k9RJKbpDVbJSv86zu3n3T2qIaj4HfMJduNuW3cI6xnnjnJSfcdRRju2gYrxUpgFtWM7VHjY73YpAdhuOpA7oOM1PFY2fNGcFBz1GycOb\/ADHCAy9DP6ejyJiQsKbGEpwRj1+9O1h43cTtB+HbHue4QdlCNOT4g5fVKjuKPAmW+9MfJ6is7byjsXkAIcHvtsaj+o+D7V2jfMWN9ucEYPgueVxOOgHtRQuROG2dqA+Bswyb4DkfUpB\/bvhJxNix4eroSrPMcGU+J5mub2UNxT3ZOEWnrGh65aeYYlNupIRIbc8TGR1B7UFtQ8M70L41EfKoDaxy87iTyoI9fb3FcbDM1hw8ubi7PqaQQ0Cp3lBLRA7AHY1KICWboH8fdBzTRuJitN5+gP8A+Jo1Wxq2wagmW9yDIS2XSWllJUCM+tWP+FBrU8lq6C\/yH1xP1aYqHVE8vdRAPShxaPiQ03d1CHxA08nn5uQzYQHN9VIPX7GrB8KLhpV21yrppC8JucVwpyptCk8isfhIPeg9UsyOrGOUc+6t9HqiO5G6PAb\/AFRNm3JcWN+j2nMg9SP5U1vOKbbDaT51\/i\/5VwjOla1SpCSAjfJ7mkV5nqiwXJOf1ruUtAdj3NLFeIF6d55C1q0kXKHKeNvD6VKaOF79+9BXXao9zuDDzSsto52V4\/fSo4\/MHNTSDDfjvOSuZRUrJNDBy\/s229TdNXkJCXnS40Tso5JwUn+lO2jRNbJuHcLlHWJmsQ7T27rURGUjlSgY7GvCGlWPLTiITw8yOV5pX4Vo329x2rulhtCRkjm9KZS7K41O+SE4KQsQkJWF4AIrrOnyrUhUmMpQTJQGHEpOATnKFfUEUvjxXpDgbYZU6o7BKU5NSa36UtXzFvRfrgj5h2Qjw4DQClKOcjnV0H0HpVfelZHE4nk4Vp0\/Das34\/SOBkZVn9JyHpNgtsiSD4i4ralZ65KRmn1Kcjao\/YHR8m0hKcJCQkD0GKkDOetcpmxuJC+soP3bQfZALiEojU1xT6On+QoJcRoi5UNRbznrRt4hgHU9yxsfF\/oKF+oWUKYUFJznNK1gnecJ2q\/u2\/YKqWs7QtfOpxgbeooM6qiBJU6o8pb\/AA8vbFWW4iMN+ZCEgdaBOprchzmSEFROQdqyM5TDWhDm5ChUK5XAoSG5PMD7CnRBLnK5dZSnEdkrXhP5Co0+01bpRYW6pHcHtS2PKjpIK3Wj3HMrJ\/hRTMA8oqvK0Ha7uppHuUH5XwLfB5x0JCQhsfU9TTfI8WS6HJLoWUHYJT5UfQdB9TSOJMdlcqWo7z\/YD\/DbH1PX+VOjdvlXBQZTh9SRzFqMMNtj1Wo7fcmjQ7eMK7hlx2SIyUt5QwAon8SiM\/8Ar\/Ks\/MT\/APWX\/wDxUuUxChK8im5b6evL\/go+\/wC0fptWf0ncP9Zjf\/jp\/wCVYWYVoxu8ZcV90SRWEqOKxzD1rHMKNAwV86ErcbnNbE\/yrQEA9a15hnGRXuFG4bivKXsMjpXNSknbGN6y4oJGQetCDivxejWP5iw2mehmQjKZT2Dzt\/7CBjdR7GiqdSS7KIolVaxq0Oi1TZn7J+1\/xLg6dbdg25xt2cE+dRPkYHqo+vtVeJs69a8ur0W3KefMg\/r5K+qh3+ifauFvhXvXUzxFhyHbEq5lLWclfuT+0o0bdDaCS1EbZiRfl4gPmKvxvH1Pt7U3j4bRIvd5XH\/\/AKnXVvc\/LYR+iFvDb4ehaNVO3SK5ysqUFlwDHm7hPtVmINqhwWEICU86AAFY3pZDtkeCwENNpSBt0rjJXyBR7Uq2rjrkm8rsenaezT4GxA5wEKPibkBzhRdY7aOdwlBQPfmqhF10teYSlCUWGlcvOpKnRkCvofr20MaitMi1zEc7T6Skjp96rpftB6vtjpjtIgXCMgFLa3mj4qU9gSOtPfR+rtoQuhc7GSk3qytbdYbPWjDhjB91W7TMFVxnB9Cl+DDdQp1QTkbnGM1KtOaHgWC9SnJ1rdmR38qaW2ohQycgHB3ok2PhtcXJRcujiSgq5kstN8iAfcd\/vRNtWg44SgqYzjHberPUdba2UPDt2EHFQlt13RPBbnwD2QvtOjmr0tDNssHyDWwefXutSR23PerAaSt6oMBmIkEIaQEgegG1d7PphlhAShoAfSpNAtga6JpW1fVjqGAeAFbaJoY01paCSfqtUQsp3Gc1xftYIyR\/CnxqMcDNdTGSRgjNL3q8pjEIAULkWocxVyimuXaQrOUD8qnzsEK38Om5+2g52rcSnwo3QhD1\/S0R4\/g5Se6Rik5skqEQplRUE70QXLcUjKUg\/akbsLlySmp2WCO6j+HBKgFylsPMFm7QWpKPR1O\/2PaoHeNCaUvYdNvlGE46nl8J4+Q\/Q9qMN0tLMlCkuMgjGOnSoDf9JPoSVRVn6UTFO0djhBz1Q\/h4yq96g4IzrA5IkSIBfZV5m3EnKcfUVYT4VrWmyaCmvvpCA5NcWoEYAwlIAH8agsm6al024rw3XCyD5mnE86FexBosaDceu2jo8lltmGH3VOuNtI5UkZI6fX+VbXrEj4dh5C90yiyCx6oKmYlrnOn9ZhoZVj90U0T3PnpJKRhCRyoHoK68yYkcxm3\/ABlubuKxj7VlhGdwmgYW7eVayu3cLmzbuZBQOh67UM+KPCpvULBcCSzJb80eQkboV7+1GiExnGehpycgMymvCW0COm9FxXH1X7moKehHZZtcqOG\/cTOHbny+oLFKnx0HCZUUE5T74\/rTrE+ILTSk\/wB8bfacTsUvRgTmrYTtBsPLLkUhtX02NMr3C\/xXCVwrYonuuG2o\/mRV0zX2H8wSnb6Iq2XFzoxn3Bx\/RV3Z4xX3UqxbNB6auNwfc2y214bafckdvvRK4UaO1Azf2rrqyYiVeXPIlhndmE2eoHYrPrROhcNZSUhhcwNMj\/NsNpbT\/wDxAqb6X0lBsxHhMAH97G5qvvayHtLWcBWWj9K16Dg5jMf3UrsjBYjNoUPwgU+tL5R0703R0hKRjp3pY0oY60pOO45KfmNDRgIFcQwBqS4qyf8AFP8AIUJtTvqS0rBzRY4h\/wDvDcDn\/Of0oParVlChnBGaWLBw8\/dOtMZjb9ggnrFBfecVjPUUKtQRUgKITvv0ov6gZytaiM5oc32KDzZT61pG7CZaxwAEH9Q2ouR3HkNBTiBzAH+NRiHNQnCBFWlQPUAUTbuyGwcAbUO5kVyLJWUoPhk5SR6elE5XthpDt7U7QZUl4JSiMTj\/AEi9vyFSuBDlTGQifO5WE\/8Aw7I5UH02Gx+pqE2+SpBGxzUxs9xKSnKFH2Ao6A5VnUfuSmbEbaR4TDfKgCm3wG\/3hUvTATc8eLgJA\/A2CVK+vp\/Cs\/2Wj\/6mr\/xJo\/0N3KYIWFzcr7Nhw966eLgbEUkDmetZ8RP7v8a3wvm8nKVFw+taqWMgkik5eQOxrUugnPasWNOF6dN+WZ8VLanMKAIT1Ge9BriVw0Y1LqGJf22H3lhY+YSlOULSOgx2+tF11tqSnlXkDOevWlBdZYbShDSfrRFW0+o\/fH3QGo6dBqkRhsDLVBNKcPkNluRcGEobR\/hMJHlQP6mp820zEbShkBIAxgVwRKI2A27VgvknOTWs8r7Dt7ivadGDT4hDA0ABd3XvLjNIJB5knBrZTnMO5ri50zmohwUXnhM86KXM5pil2Jp4HnbzUuW2HB9K4fLD1H5UZHM5n5Sh5IWyHlQX+ysdC+ZLPenKJZ0oATyYqUfJNkVgxUJ6CpH2HO7lQiuxvhNkW3pb6jel7URKe1dktDYV2SjlzUDnkhTNYAVyTGFZMcClO3tWuOu9RgrbaCki2QM5HWky4yVbYpyUEkY71xWjfbrWzXFaFoTUuN2CetJXYSeqhT243jFJnGgU71IHFaEKNS4STnCetMc62JUkgozUzfYBTsKbJEYK2Iqdr+FC6Pyh1cNLQ5iVJfZCgfWulqtzlngfo+GvDCTlKcdPb+NS2VBSaSfInO1Th27g9lE1pZ2TK0mUFeZBwT1p1iIURuKWNQ0q3UneljENA6JxUm4Y4W+MlbREbDenRggjFJGmeXoRSppCgOtQPOSpmNwlrKgDkgUsQEbEpBzSBrI3PSlTa8p2odwwiGnCVJ5AcgAUqjkFWSoUhCxmu7KhmoXDcFIDgp4ac67ilKHOQ4x1psS5gDtSpp0YBJJqBw4UwdygrxDWDqC4b\/5z+lB3U5Kufei9xBIN+nkf6T+lCHUgSSv2pUsn8Q\/dPVIZiafohjfGebmPbeh7fmN1HPTNEy7t5KhQ\/vrQ8wPvULXEK7gOELtQN8vMTQ7vkssJVyneibqFrIVtQo1QMOgepotjs8KSy8hhwtLS6pQTznfrUwt8oNgEjIzUKtwxjPapHHfSlPICd6LhO3lWGnuAaMqYx9TyWmSwyEpGNyBWn6fuP+tK\/Oo8w8kEKGd9utd\/mF\/vJ\/Kj2ynHdMcEmWr7fmRjr\/OvB9RGcVo50FZT0o3K+cQ1eMjftWfFJFcz1roOlZle7VguY71qXididhWT1rB6V7wFm1cVOEbZrweI75rZX4zWK87rNoWnie5r3OOma3r1YFm0LQLTXuZPat69XucFaloWmR61hRA610rVdbd1qWrnzpwfWtQ5y9a3rRdZlalowvGSkZrQSQdgofTNcZX+CukDH+Kj\/erzKzanbxh6itfFGc1zT1+9ZPWtmlZsCytwK+tcFubb12T1rkvp963BytHtACTuLTg5pA+BnOBTgvoaRyOlbhR7Qm9xCVAkjr0rh4A\/dFLHeg+lcamBwoiFzSykdRXRACeorI61tXu4rMLKVJzkV3QsCuSegrsn+la7itwFuHMVsl4pFap615Vak5W44XRMjJ60rYd9803jrSqP1rUgBStGU5IkjIzSluSAMGkQ7UoHaoScrcDlCLXai5epqgeqz\/KhVfm+YqyBRV1r\/wC2Jv8Avn+VDC+dHPvSdY\/eu+66BR\/ct+yHd4a\/Ee9D+\/Mk82B60RLz+FX0NQS99FUOrWLuhhqNglC9t6EWrGClwL7JUKM+oeivrQj1d+Ff+8KIjKmmHyFM0I4ANOrTgBGaaYf4R9KcW+31othKMpnDU6RyFKHpml\/gJ9DSCN+EfenKjohlquonHav\/2Q==\" width=\"301px\" alt=\"stage\"\/><\/p>\n<p>This out<a href=\"https:\/\/forex-world.net\/\">https:\/\/forex-world.net\/<\/a> came despite biotech\u2019s reputation as a risky area for investors. \u201cBiotech is very speculative,\u201d says Rachel Elfman, healthcare equity analyst at Morningstar. While successful drugs can bring in billions in revenue, that\u2019s far from guaranteed. Fortunes can rise or fall based on a single up or down decision from the U.S. Food and Drug Administration regarding a biotech company\u2019s main product.<\/p>\n<p>It makes dozens of Food and Drug Administration-approved drugs, including migraine medications, chemotherapy agents and treatments for autoimmune diseases, among others. But after watching biotech companies win big for a decade, big pharma companies have now pivoted toward innovation themselves and are investing in their own pipelines. Pfizer, for example, shed its big consumer products, generics, and veterinary divisions, and is now focused on creating innovative medicines and vaccines. As a result, big pharma companies have become more discriminating when it comes to buying biotechs.<\/p>\n<ul>\n<li>After all, the #1 stock is the cream of the crop, even when markets crash.<\/li>\n<li>From WuXi Biologics, the company licenses a panel of monoclonal antibodies.<\/li>\n<li>But after watching biotech companies win big for a decade, big pharma companies have now pivoted toward innovation themselves and are investing in their own pipelines.<\/li>\n<\/ul>\n<p>In its December omnibus legislation, Congress also made explicit the FDA\u2019s authority to require larger and expensive post-approval trials related to accelerated approval. The new reality around accelerated approval adds cost and risk to the biotech equation. In 2021 it had sales of $133 million and lost $152 million, or $3.15 per share. In Nov. 2021, at the height of the tech boom, it was over $5.5 billion. Unfortunately, Ionis has also failed on at least four drugs in the last year. This has caused some analysts to back away, with three telling investors to sell.<\/p>\n<p>Finally, as with any investment, carefully review financial statements and verify the company\u2019s claims before buying stock. Companies that only have one major project in the works are far riskier than those with multiple irons in the fire. The more products currently in development, the more likely that one will be massively successful. Most ideas are ultimately unsuccessful, and the investment is lost. Consider, for example, the story of Theranos \u2013 a biotech company that rose to dizzying heights before going completely bankrupt. INCY has patent protection for Jakafi until 2027 and it continues to see expanded use for other indications.<\/p>\n<p>WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Siga Technologies&#8217;s dividend payout ratio of 97.8% indicates that its high dividend yield might not be sustainable for the long-term. Carisma Therapeutics&#8217;s dividend payout ratio of 0% indicates that its high dividend yield might not be sustainable for the long-term.<\/p>\n<p>We\u2019d like to share more about how we work and what drives our day-to-day business. Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data. \u201cManagement has been focused on diversifying its portfolio, with the new drug approvals of Zepzelca , Rylaze , and Xywav .<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Contents: What are biotech stocks? What Are Biotechnology Stocks? Best Biotech Stocks: Twist Bioscience (TWST) Top Stocks To Invest In Biotechnology stocks are the instruments that help fund biotech companies. Many biotech companies fly under the radar of consumers and retail investors. That\u2019s because once they develop new drug technology, they sell it to a [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_eb_attr":"","_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[169],"tags":[],"class_list":["post-113995","post","type-post","status-publish","format-standard","hentry","category-forex-trading"],"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false},"uagb_author_info":{"display_name":"admin","author_link":"https:\/\/www.aquatb.com\/?author=1"},"uagb_comment_info":0,"uagb_excerpt":"Contents: What are biotech stocks? What Are Biotechnology Stocks? Best Biotech Stocks: Twist Bioscience (TWST) Top Stocks To Invest In Biotechnology stocks are the instruments that help fund biotech companies. Many biotech companies fly under the radar of consumers and retail investors. That\u2019s because once they develop new drug technology, they sell it to a&hellip;","_links":{"self":[{"href":"https:\/\/www.aquatb.com\/index.php?rest_route=\/wp\/v2\/posts\/113995","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.aquatb.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.aquatb.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.aquatb.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.aquatb.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=113995"}],"version-history":[{"count":1,"href":"https:\/\/www.aquatb.com\/index.php?rest_route=\/wp\/v2\/posts\/113995\/revisions"}],"predecessor-version":[{"id":113996,"href":"https:\/\/www.aquatb.com\/index.php?rest_route=\/wp\/v2\/posts\/113995\/revisions\/113996"}],"wp:attachment":[{"href":"https:\/\/www.aquatb.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=113995"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.aquatb.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=113995"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.aquatb.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=113995"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}